What smart money is saying about WuXi AppTec Co., Ltd.

Position history

Every position in WuXi AppTec Co., Ltd. on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 1 position

• HoldsBaron Emerging Markets Select ETF

  September 2026

  “WuXi AppTec Co., Ltd. is China’s leading contract research, development, and manufacturing organization (CRDMO) for small-molecule and peptide drugs. Shares rose after the company reported strong first-half results in early August and nearly doubled its full-year revenue growth guidance, raising the range to 35% to 39%. Results were supported by the largest sequential backlog addition on record and 40% growth in new orders. Small-molecule development and manufacturing grew 73%, driven by increasing drug-manufacturing complexity, while the peptide business continued to scale into the obesity supply chain. Roughly 80% of new late-stage projects originated from WuXi’s earlier-stage work, providing further evidence that its follow-the-molecule strategy continues to work as intended. Separately, a federal court blocked enforcement of the U.S. Department of Defense’s “Chinese military company” designation that had weighed on shares, finding WuXi likely to succeed on the merits. We remain shareholders and continue to view WuXi as one of the best ways to gain exposure to the structural growth of outsourced drug chemistry.”

  Show more
  Read the letter→
  WuXi AppTec Co., Ltd.